Open AccessA post hoc analysis of two Phase III trials showing the efficacy and tolerability of ceftobiprole in East Asian patients
Author(s) -
Haihui Huang,
Lei Gao,
Marc Engelhardt,
Mikaël Saulay,
Kamal Hamed
Publication year - 2021
Publication title -
future microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.797
H-Index - 82
eISSN - 1746-0921
pISSN - 1746-0913
DOI - 10.2217/fmb-2021-0121
Subject(s) - tolerability , post hoc analysis , post hoc , medicine , clinical trial , oncology , pharmacology , adverse effect
Aim: To evaluate the efficacy and safety of ceftobiprole in patients from East Asia. Materials & methods: A post hoc analysis was conducted of two randomized, double-blind, Phase III studies in patients with community- or hospital-acquired pneumonia. Results: Findings for East Asian patients were consistent with the overall study populations. A trend toward higher microbiological eradication rates and numerically lower rates of all-cause mortality were reported for ceftobiprole versus comparators (all-cause mortality [intent-to-treat]: community-acquired pneumonia, 1.5 vs 2.8%; hospital-acquired pneumonia excluding ventilator-associated pneumonia, 5.9 vs 11.4%). The incidence of adverse events was similar between treatment groups. Conclusion: This post hoc analysis supports the efficacy and tolerability of ceftobiprole in East Asian patients. ClinicalTrials.gov trial identifiers: NCT00326287 , NCT00210964 , NCT00229008 .